Article
Tampa, Fla. — Although development of melanoma vaccines based on dendritic cells (DCs) lags behind that of more established approaches, it's rapidly moving from the lab bench into clinical trials.
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.